The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Delayed platelet recovery in patients with myelofibrosis undergoing allogeneic transplantation
In this video, Patrizia Chiusolo, MD, PhD, Agostino Gemelli University Policlinic, Rome, Italy, briefly discusses the impact of delayed platelet recovery in patients with myelofibrosis undergoing allogeneic stem cell transplantation, noting higher rates of non-relapse mortality in patients with delayed engraftment. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This paper was very important because we evaluated the engraftment of platelets at 100 days after transplant to a level of 50,000 platelets. We demonstrated that the reduction in the engraftment, the latency in engraftment, was associated with a higher rate of non-relapsed mortality in patients with delayed engraftment. Some factors are predictive of delay in platelet engraftment, and these are the kind of donor we use, the rate of fibrosis, the dose of CD34 cells that we use in these patients, and also a favorable outcome is the splenectomy, which makes the engraftment easier earlier at 100 days after the transplant...
This paper was very important because we evaluated the engraftment of platelets at 100 days after transplant to a level of 50,000 platelets. We demonstrated that the reduction in the engraftment, the latency in engraftment, was associated with a higher rate of non-relapsed mortality in patients with delayed engraftment. Some factors are predictive of delay in platelet engraftment, and these are the kind of donor we use, the rate of fibrosis, the dose of CD34 cells that we use in these patients, and also a favorable outcome is the splenectomy, which makes the engraftment easier earlier at 100 days after the transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
